ERYTech Pharma SA Sponsored ADR

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

PHAXIAM Therapeutics SA operates as a biopharmaceutical company. It engages in the development of treatments for resistant bacterial infections. The firm develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics. The company was founded in 2004 and is headquartered in Lyon, France.

LYON, France and CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced the appoint ment of Dr. Stewart Craig as its Chief Techn ical O fficer (CTO) and member of the executive team. D r. Craig brings 3 5 years of experience in the development, manufactur ing , technical operations, quality systems and regulatory affairs for complex biologics and cell & gene therapies worldwide.

ERYTECH Appoints Stewart Craig as Chief Technical Officer

ERYTECH is progressing a phase 3 trial in pancreatic cancer. The drug, reformulated L-asparaginase, has known anti-cancer properties but its safety profile needs to be good.

ERYTECH: Trials In Pancreatic Cancer

Article 223-16 of general regulation of French Autorité des Marchés Financiers

Monthly information related to total number of voting rights and shares composing the share capital - September 30, 2020

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q2 2020 Results - Earnings Call Transcript

LYON, France, Sept.  21, 2020  (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances in red blood cells (the "Company"), today announced the implementation of an at-the-market program allowing the Company to issue and sell ordinary shares in the form of American Depositary Shares ("ADSs"), to eligible investors at market prices, with aggregate gross sales proceeds of up to $30,000,000 (subject to a regulatory limit of 20% dilution), from time to time, pursuant to the terms of a sales agreement with Cowen  acting as sales agent .

ERYTECH establishes a financing facility with the implementation of an at-the-market program on Nasdaq with Cowen

LYON, France, Sept.  16, 2020  (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells,  today announced that it will host its second quarter 2020 conference call and webcast on Tuesday, September 22, 2020, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.

ERYTECH to Host on September 22, 2020 Second Quarter 2020 Conference Call and Business Update

LYON, France and CAMBRIDGE, Mass., Sept.  14, 2020  (GLOBE NEWSWIRE) -- ERYTECH Pharma  (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announces the hosting of a Key Opinion Leader (KOL) Event to discuss the medical need in pancreatic cancer and the potential role of eryaspase in this setting.  

ERYTECH Announces the Hosting of a KOL Event as the TRYbeCA-1 Phase 3 Trial in Second-line Pancreatic Cancer Nears Complete Enrollment

LYON, France, Sept.  14, 2020  (GLOBE NEWSWIRE) --   Article 223-16 of general regulation of French Autorité des Marchés Financiers    Lyon – France

Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2020

Erytech is a company with a promising novel method targeting the large cancer market with unmet needs.

Erytech Pharma: Exploring New Ways To Battle Cancer

LYON, France, Aug.  06, 2020  (GLOBE NEWSWIRE) --    Article 223-16 of general regulation of French Autorité des Marchés Financiers  Lyon – France

Monthly information related to total number of voting rights and shares composing the share capital – July 31, 2020

LYON, France, July  10, 2020  (GLOBE NEWSWIRE) --   Article 223-16 of general regulation of French Autorité des Marchés Financiers    Lyon – France

Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2020

LYON, France and CAMBRIDGE, Mass., June  26, 2020  (GLOBE NEWSWIRE) -- ERYTECH Pharma  (Euronext: ERYP - Nasdaq: ERYP)  announced that its 2020 Annual General Meeting  was held in Lyon on Friday, June 26, 2020.

ERYTECH Reports Voting Results from its Annual General Meeting Held on June 26, 2020

Agreement with Alpha Blue Ocean and European High Growth Opportunities Securitization Fund for the issuance of zero-coupon convertible notes with share warrants attached Agreement with Alpha Blue Ocean and European High Growth Opportunities Securitization Fund for the issuance of zero-coupon convertible notes with share warrants attached

ERYTECH extends its cash horizon by implementing a convertible bond financing

LYON, France, June  09, 2020  (GLOBE NEWSWIRE) --   Article 223-16 of general regulation of French Autorité des Marchés Financiers  Lyon – France

Monthly information related to total number of voting rights and shares composing the share capital – May 30, 2020

LYON, France and CAMBRIDGE, Mass., June  09, 2020  (GLOBE NEWSWIRE) -- ERYTECH Pharma  (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today  provided an update on the ongoing Phase 2 trial, sponsored by the Nordic Society of Paediatric Haematology and Oncology (NOPHO) of eryaspase in second-line acute lymphoblastic leukemia (ALL) patients.

ERYTECH Provides Update on Phase 2 Investigator Sponsored Trial of Eryaspase in Second-Line Acute Lymphoblastic Leukemia

Erytech Pharma SA Sponsored ADR (ERYP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's What You Should Know

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q1 2020 Results - Earnings Call Transcript

LYON, France, May  07, 2020  (GLOBE NEWSWIRE) --   Article 223-16 of general regulation of French Autorité des Marchés Financiers  Lyon – France

Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2020

Conference call and webcast on Thursday, May 7 at 2:30 pm CET/8:30 am ET

ERYTECH Provides Business Update and Reports Cash Balance at End of Q1 2020

LYON, France and CAMBRIDGE, Mass., May  05, 2020  (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced it will be part of EVIDENCE, a public-private consortium supported by the European Union in the framework of the EU Horizon 2020 program.

ERYTECH engages in collaborative partnership with  EU Horizon 2020 EVIDENCE consortium

LYON, France and CAMBRIDGE, Mass., April  28, 2020  (GLOBE NEWSWIRE) -- ERYTECH Pharma  (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells,  announced today that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track Designation for the development of a second-line treatment of patients with metastatic pancreatic cancer.

ERYTECH Granted U.S. FDA Fast Track Designation for eryaspase in Second-Line Pancreatic Cancer

LYON, France and CAMBRIDGE, Mass., April  28, 2020  (GLOBE NEWSWIRE) -- ERYTECH Pharma  (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing red blood cell-based cancer therapeutics, today   provided an update on the pivotal Phase 3 clinical trial for advanced metastatic pancreatic cancer (TRYbeCA-1), which is evaluating the efficacy and safety of ERYTECH’s lead product candidate eryaspase in combination with chemotherapy as second-line therapy.

ERYTECH Provides Update on the TRYbeCA-1 Phase 3 Clinical Trial of Eryaspase in Second Line Pancreatic Cancer

LYON, France, April  20, 2020  (GLOBE NEWSWIRE) -- ERYTECH Pharma  (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing red blood cell-based cancer therapeutics, today  provided an update on the pivotal Phase 3 clinical trial for advanced metastatic pancreatic cancer (TRYbeCA-1), which is evaluating the efficacy and safety of ERYTECH’s lead product candidate eryaspase in combination with chemotherapy as second-line therapy.

ERYTECH Provides Update on the TRYbeCA-1  Phase 3 Clinical Trial of Eryaspase in Second Line Pancreatic Cancer

LYON, France, April  06, 2020  (GLOBE NEWSWIRE) --   Article 223-16 of general regulation of French Autorité des Marchés Financiers    Lyon – France

Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2020

LYON, France and CAMBRIDGE, Mass., March  19, 2020  (GLOBE NEWSWIRE) -- ERYTECH Pharma  (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells,  announced that it had filed its 2019 Universal Registration Document for the year ended December 31, 2019, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2019 with the U.S. Securities and Exchange Commission (SEC).

News for ERYTech Pharma SA Sponsored ADR Stock (ERYP)